^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

gotistobart (BNT316)

i
Other names: BNT-316, ONC392, BNT316, ONC-392, ONC 392, BNT 316
Company:
BioNTech, OncoC4
Drug class:
CTLA4 inhibitor
1d
Enrollment open • Metastases
|
LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
docetaxel • gotistobart (BNT316)
29d
PRESERVE-004: ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer (clinicaltrials.gov)
P2, N=58, Active, not recruiting, OncoC4, Inc. | Recruiting --> Active, not recruiting
Enrollment closed
|
Keytruda (pembrolizumab) • gotistobart (BNT316)
30d
PRESERVE-003: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors (clinicaltrials.gov)
P3, N=600, Active, not recruiting, OncoC4, Inc. | Recruiting --> Active, not recruiting
Enrollment closed • Metastases
|
LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
docetaxel • gotistobart (BNT316)
6ms
PRESERVE-001: Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC (clinicaltrials.gov)
P1/2, N=733, Recruiting, OncoC4, Inc. | Trial completion date: Dec 2024 --> Dec 2027 | Trial primary completion date: Jun 2024 --> Jun 2026
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • docetaxel • gotistobart (BNT316)
10ms
PRESERVE-001: Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC (clinicaltrials.gov)
P1/2, N=914, Recruiting, OncoC4, Inc. | Phase classification: P1a/1b --> P1/2 | Trial primary completion date: Dec 2023 --> Jun 2024
Phase classification • Trial primary completion date • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • gotistobart (BNT316)
12ms
PRESERVE-006: ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC (clinicaltrials.gov)
P1/2, N=144, Recruiting, OncoC4, Inc. | Not yet recruiting --> Recruiting
Enrollment open
|
FOLH1 positive
|
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • gotistobart (BNT316)
1year
PRESERVE-006: ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC (clinicaltrials.gov)
P1/2, N=144, Not yet recruiting, OncoC4, Inc. | Phase classification: P2 --> P1/2 | N=90 --> 144 | Trial completion date: Dec 2026 --> Jun 2027 | Initiation date: Sep 2023 --> Dec 2023 | Trial primary completion date: Dec 2025 --> Jun 2026
Phase classification • Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date • Metastases
|
FOLH1 positive
|
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • gotistobart (BNT316)
over1year
PRESERVE-009: Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=18, Recruiting, OncoC4, Inc. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
gotistobart (BNT316) • AI-061
over1year
Enrollment open
|
LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
docetaxel • gotistobart (BNT316)
over1year
New P1 trial • Metastases
|
gotistobart (BNT316)
almost2years
New P3 trial • Metastases
|
LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
docetaxel • gotistobart (BNT316)
almost2years
PRESERVE-004: ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer (clinicaltrials.gov)
P2, N=58, Recruiting, OncoC4, Inc. | Not yet recruiting --> Recruiting
Enrollment open
|
BRCA (Breast cancer early onset)
|
BRCA mutation
|
Keytruda (pembrolizumab) • gotistobart (BNT316)
almost2years
PRESERVE-004: ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer (clinicaltrials.gov)
P2, N=58, Not yet recruiting, OncoC4, Inc. | Initiation date: Sep 2022 --> Dec 2022
Trial initiation date
|
BRCA (Breast cancer early onset)
|
BRCA mutation
|
Keytruda (pembrolizumab) • gotistobart (BNT316)
over2years
New P2 trial
|
BRCA (Breast cancer early onset)
|
BRCA mutation
|
Keytruda (pembrolizumab) • gotistobart (BNT316)
almost3years
PRESERVE-001: Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC (clinicaltrials.gov)
P1a/1b, N=413, Recruiting, OncoC4, Inc. | N=300 --> 413 | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
Clinical • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene)
|
EGFR mutation
|
Keytruda (pembrolizumab) • Tagrisso (osimertinib) • gotistobart (BNT316)
over3years
PRESERVE-001: Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC (clinicaltrials.gov)
P1a/1b, N=300, Recruiting, OncoC4, Inc. | N=91 --> 300 | Trial completion date: Jul 2023 --> Dec 2023 | Trial primary completion date: Jul 2022 --> Dec 2022
Clinical • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Keytruda (pembrolizumab) • Tagrisso (osimertinib) • gotistobart (BNT316)
over4years
[VIRTUAL] First-in-human phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy. (ASCO 2020)
The trial consists of a dose-finding, dose escalation or de-escalation, Phase IA component aimed at defining the recommended phase II dose for ONC-392 in combination with a standard dose of Pembrolizumab (RP2D-C), then progressing into two parallel, single arm, Phase IB expansion cohorts to test for safety and initial efficacy in two groups of patients with NSCLC: Stage IV NSCLC anti-PD(L)1 immunotherapy naïve with PD-L1-positive (PD-L1 TPS ≥ 1%); Stage IV NSCLC refractory/resistant to anti-PD(L)1 immunotherapy. Research Funding: U.S. National Institutes of Health, Pharmaceutical/Biotech Company
Clinical • P1/2 data
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
Keytruda (pembrolizumab) • gotistobart (BNT316)